Step by Stepa HemeOncBuddy patient portal

Lenvatinib

Illustration: Lenvatinib

Say it: len-VA-tih-nib · Brand names: Lenvima

Lenvatinib is a targeted pill that blocks several growth signals and cuts off the blood supply tumors need.

What it is

Tumors need new blood vessels to grow. Lenvatinib blocks signals, including one called VEGF, that tell new blood vessels to form. It also blocks other signals that help cancer cells grow.

Often used for

How you get it

It is a capsule you take by mouth once a day, with or without food. People usually take it for as long as it works and side effects are OK. Your schedule may be different.

Common side effects and what helps

Call your care team right away if you have

Before you start, tell your team

Good to know

At home

Questions to ask

Side effect guides

Sources

Quick answers

What is Lenvatinib?
Lenvatinib is a targeted pill that blocks several growth signals and cuts off the blood supply tumors need. Brand names: Lenvima.
What is Lenvatinib used for?
thyroid cancer that no longer responds to radioactive iodine; kidney cancer, with pembrolizumab or everolimus; liver cancer; endometrial cancer, with pembrolizumab.
How is Lenvatinib given?
It is a capsule you take by mouth once a day, with or without food. People usually take it for as long as it works and side effects are OK. Your schedule may be different.
What are the common side effects of Lenvatinib?
High blood pressure. Feeling tired. Diarrhea. Less appetite and weight loss. Joint or muscle pain. Mouth sores. Red, sore, or peeling skin on the palms and soles. Hoarse voice.
When should I call my care team while taking Lenvatinib?
Bad headache, or blood pressure higher than your team told you to expect; Bleeding that will not stop, black or bloody stools, or coughing up blood; Chest pain, or numbness or weakness on one side, or trouble speaking; Bad belly pain; Confusion, seizures, or sudden vision changes; Yellow skin or eyes, dark urine, or pain on the right side of your belly.

Last updated: 2026-10-27. Medically reviewed by Veli Bakalov, MD, medical oncologist (October 2026). General education from Step by Step, the patient portal of HemeOncBuddy.